TrinetX Study of Hypereosinophilic Syndrome (HES) without an identifiable non-haematological secondary cause

Trial Identifier:	D3254R00004
Sponsor:	AstraZeneca
NCTID::	NCT06172751
Start Date:	December 2023
Primary Completion Date:	April 2024
Study Completion Date:	April 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
USA, Massachusetts	Cambridge, Massachusetts, USA, 02140

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.